FindTrial
Sign In

PEEL-224

DRUG3 trials

Sponsors

Peel Therapeutics Inc, David S Shulman, MD, Theodore Laetsch

Conditions

Advanced Solid TumorDesmoplastic Small Round Cell TumorOsteosarcomaRefractory NeuroblastomaRefractory RhabdomyosarcomaRefractory SarcomaRefractory Solid TumorsRelapsed Neuroblastoma

Phase 1

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
RecruitingNCT05329103
Peel Therapeutics IncAdvanced Solid Tumor
Start: 2022-07-11End: 2026-10-01Target: 65Updated: 2026-05-15
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RecruitingNCT06709495
David S Shulman, MDDesmoplastic Small Round Cell Tumor, Osteosarcoma, Refractory Sarcoma +3
Start: 2025-01-27End: 2029-09-01Target: 63Updated: 2026-02-19
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingNCT06721689
Theodore LaetschRefractory Neuroblastoma, Refractory Rhabdomyosarcoma, Refractory Solid Tumors +3
Start: 2025-03-23End: 2031-04-01Target: 59Updated: 2026-07-22

Related Papers

Abstract 1157: Preclinical evaluation of PEG-[SN22]4 (PEEL-224), a multivalent polymeric camptothecin prodrug, in pediatric solid tumor patient-derived xenograft models
Cancer Research2026-04-03
Abstract B001: Phase 1/2 trial to evaluate the safety and efficacy of PEEL-224 in combination with vincristine and temozolomide in adolescents and young adults with relapsed or refractory sarcomas
Molecular Cancer Therapeutics2025-10-22
456 100% complete response to PEEL-224 in combination with PD-1 blockade in a syngeneic mouse model of colon cancer
Regular and Young Investigator Award Abstracts2023-10-31